Beam Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M |
| Research and development | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M |
| Operating expenses | $523.4M | $479.1M | $554.2M | $399.4M | $444.3M |
| Operating income | -$383.7M | -$415.6M | -$176.5M | -$338.5M | -$392.5M |
| Pretax income | -$80.0M | -$376.7M | -$131.2M | -$260.2M | -$370.6M |
| Income tax expense | $0 | $39,000 | $1.4M | $3.4M | $0 |
| Net income | -$80.0M | -$376.7M | -$132.5M | -$289.1M | -$370.6M |
| Balance Sheet | |||||
| Cash and equivalents | $294.9M | $282.0M | $435.9M | $232.8M | $560.0M |
| Current assets | $1.3B | $878.1M | $1.2B | $1.1B | $1.3B |
| Total assets | $1.5B | $1.1B | $1.5B | $1.3B | $1.5B |
| Current liabilities | $96.9M | $182.1M | $205.6M | $223.6M | $213.4M |
| Total liabilities | $242.8M | $370.3M | $478.4M | $608.2M | $647.7M |
| Stockholders' equity | $1.2B | $733.5M | $981.3M | $733.5M | $826.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$345.1M | -$347.2M | -$149.2M | $22.5M | -$66.3M |
| Depreciation and amortization | $22.3M | $21.9M | $20.0M | $14.1M | $7.5M |
| Stock-based compensation | $94.2M | $120.7M | $98.6M | $84.3M | $43.6M |
| Capital expenditure | $14.9M | $8.9M | $33.7M | $49.0M | $46.8M |
| Free cash flow | -$360.0M | -$356.2M | -$182.9M | -$26.4M | -$113.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 102.9M · Free float 94.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.